This article is more than 5 years old. Information may no longer be current.
Advances and obstacles apparent in osteoporosis care
Click Here to Manage Email Alerts
American Association of Clinical Endocrinologists 17th Annual Meeting & Clinical Congress
Current tools and recommendations available to physicians allow them to identify and treat patients with osteoporosis more successfully than ever before, according to Nelson B. Watts, MD, FACP, MACE.
With the approval of once-yearly bisphosphonates such as Reclast (zoledronic acid, Novartis), treating osteoporosis has become easier for both physicians and patients. The medication, which is administered intravenously, provides patients with year-long bone protection.
“Bisphosphonates have become the agents of choice for first-line treatment of osteoporosis,” said Watts, director of the University of Cincinnati Bone Health and Osteoporosis Center.
Recommendations for osteoporosis care
The National Osteoporosis Foundation recently released guidelines for the diagnosis and treatment of osteoporosis to provide physicians with decision making tools to use in their clinical practice. In addition to providing guidelines for pharmacological therapy, Watts highlighted important features of the guidelines:
- Offers insight into the diagnosis and treatment of osteoporosis in men over the age of 50 years.
- Includes black, Asian, Hispanic and other postmenopausal women when identifying risk factors of osteoporosis.
- Applies FRAX to estimate the 10-year absolute fracture risk from low bone mass or osteoporosis.
Obstacles
Despite the advancements in both the diagnosis and treatment of osteoporosis, fiscal and health care issues create barriers for both physicians and patients. Watts highlighted these hurdles, which include Medicare cuts that will decrease patients’ access to dual energy x-ray absorptiometry. Reimbursement rates much lower than the cost of performing the procedures threaten to cause health care providers to eliminate the use of DXA in their facilities.
“If the cuts go on as planned, there will be no more DXAs in clinical centers. If that bothers you, get involved,” he said.
Watts recommended contacting organizations like the AACE, National Osteoporosis Foundation and the International Society for Clinical Densitometry. He urged physicians to contact local representatives and senators to ask them to support a bill to roll back DXA reimbursement rates to the 2006 rates.
“There are clearly important public health issues involved in osteoporosis. The decrease in DXA reimbursement is a serious threat to accessibility to our patients and would even worsen the current problem of under diagnosis,” said Watts. – by Stacey L. Adams
For more information:
- Watts NB. Osteoporosis: what’s new and what’s next. Presented at: the American Association of Clinical Endocrinologists 17th Annual Meeting & Clinical Congress; May 14-18, 2008; Orlando, Fla.